CBIZ Investment Advisory Services LLC Takes Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

CBIZ Investment Advisory Services LLC acquired a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 600 shares of the biopharmaceutical company’s stock, valued at approximately $29,000.

Other hedge funds also recently made changes to their positions in the company. Heck Capital Advisors LLC purchased a new stake in shares of Halozyme Therapeutics during the fourth quarter valued at approximately $29,000. Smartleaf Asset Management LLC raised its stake in shares of Halozyme Therapeutics by 29.2% during the fourth quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 197 shares during the period. Venturi Wealth Management LLC purchased a new stake in shares of Halozyme Therapeutics during the fourth quarter valued at approximately $69,000. Parkside Financial Bank & Trust increased its stake in shares of Halozyme Therapeutics by 21.8% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company’s stock worth $86,000 after buying an additional 322 shares during the last quarter. Finally, Centaurus Financial Inc. bought a new stake in shares of Halozyme Therapeutics in the third quarter worth $127,000. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently issued reports on the stock. Benchmark restated a “buy” rating and issued a $75.00 price target on shares of Halozyme Therapeutics in a research note on Thursday, February 20th. Wells Fargo & Company dropped their price target on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. HC Wainwright restated a “buy” rating on shares of Halozyme Therapeutics in a research note on Thursday, March 6th. Finally, Piper Sandler lifted their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research note on Friday, January 10th. Four research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $62.78.

Insider Activity

In other news, SVP Michael J. Labarre sold 1,697 shares of the business’s stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $58.28, for a total transaction of $98,901.16. Following the completion of the transaction, the senior vice president now owns 173,756 shares of the company’s stock, valued at approximately $10,126,499.68. The trade was a 0.97 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Jeffrey William Henderson sold 10,000 shares of the business’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $50.01, for a total transaction of $500,100.00. Following the transaction, the director now directly owns 43,611 shares of the company’s stock, valued at approximately $2,180,986.11. This trade represents a 18.65 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 31,697 shares of company stock valued at $1,754,451. 2.40% of the stock is currently owned by company insiders.

Halozyme Therapeutics Stock Up 2.0 %

HALO stock opened at $62.27 on Friday. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15. Halozyme Therapeutics, Inc. has a 1-year low of $37.73 and a 1-year high of $65.53. The firm has a fifty day moving average price of $57.05 and a two-hundred day moving average price of $54.70. The firm has a market cap of $7.67 billion, a price-to-earnings ratio of 18.15, a PEG ratio of 0.42 and a beta of 1.32.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.17 by $0.02. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The company had revenue of $298.01 million during the quarter, compared to the consensus estimate of $285.74 million. Research analysts predict that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.